◎ Sugi Atlas

Atlas / Disease / Seborrheic dermatitis

Seborrheic dermatitis

disease
On this page

Also known as cradle Capseborrheaseborrheic dermatitis (disease)seborrheic eczemaskin seborrheic

Summary

Seborrheic dermatitis (MONDO:0006608) is a disease with 9 cohort genes (57 GWAS associations across 14 studies) and 37 clinical trials. Top therapeutic interventions include ciclopirox, ketoconazole, and levoketoconazole.

At a glance

  • Cohort genes: 9
  • GWAS associations: 57
  • Clinical trials: 37

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameseborrheic dermatitis
Mondo IDMONDO:0006608
EFOEFO:1000764
MeSHD012628
DOIDDOID:8741
ICD-10-CML21
NCITC111888
UMLSC0036508
MedGen19912
Is cancer (heuristic)no

Also known as: cradle Cap · seborrhea · seborrheic dermatitis · seborrheic dermatitis (disease) · seborrheic eczema · skin seborrheic

Data availability: 57 GWAS associations (14 studies) · 1 HPO phenotype.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › seborrheic dermatitis

Related subtypes (32): spongiotic dermatitis, atopic eczema, psoriasis, contact dermatitis, urticaria, acneiform dermatitis, acrodermatitis, folliculitis, granuloma annulare, granulomatous dermatitis, lichen planus, neurodermatitis, neurotic excoriation, parapsoriasis, pityriasis rosea, acanthosis nigricans, dermatosis papulosa nigra, lichen sclerosus et atrophicus, vitiligo, acne, porphyria cutanea tarda, dermatomyositis, acute generalized exanthematous pustulosis, hydroa vacciniforme, autoimmune bullous skin disease, cutaneous vasculitis, skin infection, intertrigo, lipodermatosclerosis, exfoliative dermatitis, radiodermatitis, food dermatitis

Subtypes (1): seborrheic infantile dermatitis

Genetics & variants

GWAS landscape

57 GWAS associations across 14 studies. Top hits map to 31 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs122035924e-71IRF4C0.21
rs121883003e-57IL12B-AS1A0.22
rs2414542e-50TAP2A0.14
rs18050077e-34MC1RC0.17
rs111508492e-27CARD14G0.09
rs80462182e-23PRSS22 - FLYWCH2C0.09
chr16:29107364e-23G0.09
rs2688901e-21KLK6 - KLK7G0.11
rs77004884e-19FBXO38-DT, SPINK5G0.08
rs127224967e-19IL2RAA0.11
rs12505632e-18ZMIZ1G0.08
rs168919826e-18SLC45A2C0.2
rs11268092e-17TYRG0.08
rs345364436e-17TYK2G0.17
rs127439747e-17IL23RG0.07
rs618396603e-16IL2RAC0.12
chr5:1317932861e-15C0.07
chr5:1474656311e-15C0.07
chr11:616054992e-15T0.07
rs18924972e-15ZMIZ1C0.08
rs741784372e-15ZBTB7AG0.07
chr3:715369742e-14A0.07
rs68666143e-14IRF1, CARINHA0.06
rs129138324e-14HERC2A0.07
rs60596555e-14RALYA0.11
rs66022887e-14PRPF38AP1 - LINC00708G0.07
chr18:518411475e-13T0.06
rs2008681875e-13FAM8A1G0.16
rs558632312e-12FOXP1A0.06
chr2:1195902883e-12C0.07

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90476171Verma A202431,107394,738Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473921UK Biobank Whole-Genome Sequencing Consortium20259,292449,148Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90478784Verma A20244,277113,844Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480445Verma A20244,277113,844Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90727028Kim HI20263,13240,894Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90727269Kim HI20263,11440,912Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90478783Verma A20242,51054,996Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90080338Backman JD20212,156379,083Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084324Backman JD20212,156379,083Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90651856Liu TY20251,601218,583Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding6
Tier 2: splice/UTR2
Tier 3: regulatory0
Tier 4: intronic/intergenic38

MAF distribution

BucketVariants
common (>=0.05)43
low_freq (0.01-0.05)3
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant24
unknown7
intergenic_variant6
missense_variant6
3_prime_UTR_variant1
non_coding_transcript_exon_variant1
5_prime_UTR_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs122035926396321C>G,T0.16intron_variantIRF44e-71Tier 4: intronic/intergenic
rs121883005159402519A>G,T0.088intergenic_variantIL12B-AS13e-57Tier 4: intronic/intergenic
rs241454632828367A>C,G0.2513_prime_UTR_variantTAP22e-50Tier 2: splice/UTR
rs18050071689919709C>A,G,T0.082missense_variantMC1R7e-34Tier 1: coding
rs111508491780202697G>A,C,T0.498non_coding_transcript_exon_variantCARD142e-27Tier 4: intronic/intergenic
rs8046218162858702C>T0.33intron_variantPRSS22 - FLYWCH22e-23Tier 4: intronic/intergenic
chr16:29107360.3134e-23Tier 4: intronic/intergenic
rs2688901950971418G>A0.196intron_variantKLK6 - KLK71e-21Tier 4: intronic/intergenic
rs77004885148094104G>A,C0.477intron_variantFBXO38-DT, SPINK54e-19Tier 4: intronic/intergenic
rs12722496106054704A>G0.107intron_variantIL2RA7e-19Tier 4: intronic/intergenic
rs12505631079287626G>C0.309intron_variantZMIZ12e-18Tier 4: intronic/intergenic
rs16891982533951588C>A,G0.038missense_variantSLC45A26e-18Tier 1: coding
rs11268091189284793G>A0.283missense_variantTYR2e-17Tier 1: coding
rs345364431910352442G>C,T0.049missense_variantTYK26e-17Tier 1: coding
rs12743974167242674G>A,C,T0.406intron_variantIL23R7e-17Tier 4: intronic/intergenic
rs61839660106052734C>T0.075intron_variantIL2RA3e-16Tier 4: intronic/intergenic
chr5:1317932860.4161e-15Tier 4: intronic/intergenic
chr5:1474656310.4821e-15Tier 4: intronic/intergenic
chr11:616054990.3392e-15Tier 4: intronic/intergenic
rs18924971079283950C>T0.25intron_variantZMIZ12e-15Tier 4: intronic/intergenic
rs74178437194056862G>A,C,T0.3815_prime_UTR_variantZBTB7A2e-15Tier 2: splice/UTR
chr3:715369740.3222e-14Tier 4: intronic/intergenic
rs68666145132451445A>G,T0.353intron_variantIRF1, CARINH3e-14Tier 4: intronic/intergenic
rs129138321528120472A>C,G0.241intron_variantHERC24e-14Tier 4: intronic/intergenic
rs60596552034077942A>G0.092intron_variantRALY5e-14Tier 4: intronic/intergenic
rs6602288108175958G>A,C0.252intron_variantPRPF38AP1 - LINC007087e-14Tier 4: intronic/intergenic
chr18:518411470.2795e-13Tier 4: intronic/intergenic
rs200868187617602639G>A,T0.033missense_variantFAM8A15e-13Tier 1: coding
rs55863231371492348A>C,G,T0.286intron_variantFOXP12e-12Tier 4: intronic/intergenic
chr2:1195902880.2623e-12Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
PRICKLE2Orphanet:178469Autosomal dominant non-syndromic intellectual disability
PRICKLE2Orphanet:402082Progressive myoclonic epilepsy type 5

Cohort genes → proteins

9 cohort genes, 9 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only9

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TACR1HGNC:11526ENSG00000115353P25103Substance-P receptorgwas
MAST4HGNC:19037ENSG00000069020O15021Microtubule-associated serine/threonine-protein kinase 4gwas
PRICKLE2HGNC:20340ENSG00000163637Q7Z3G6Prickle-like protein 2gwas
ELAPOR2HGNC:21945ENSG00000164659A8MWY0Endosome/lysosome-associated apoptosis and autophagy regulator family member 2gwas
SENP2HGNC:23116ENSG00000163904Q9HC62Sentrin-specific protease 2gwas
EVA1AHGNC:25816ENSG00000115363Q9H8M9Protein eva-1 homolog Agwas
SHISA6HGNC:34491ENSG00000188803Q6ZSJ9Protein shisa-6gwas
PIRTHGNC:37239ENSG00000233670P0C851Phosphoinositide-interacting proteingwas
GRM3HGNC:4595ENSG00000198822Q14832Metabotropic glutamate receptor 3gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TACR1Substance-P receptorReceptor for the tachykinin substance P, also able to bind and respond to tachynins neurokinin A/substance K and neurokinin B/neuromedin-K.
PRICKLE2Prickle-like protein 2Is involved in the organization and maintenance of axon initial segment (AIS) architecture, likely cooperating with IGSF9B to regulate ANK3/ANKG localization to AIS.
ELAPOR2Endosome/lysosome-associated apoptosis and autophagy regulator family member 2Functions as a regulator of the BMP signaling pathway and may be involved in epidermal differentiation.
SENP2Sentrin-specific protease 2Protease that catalyzes two essential functions in the SUMO pathway.
EVA1AProtein eva-1 homolog AActs as a regulator of programmed cell death, mediating both autophagy and apoptosis.
SHISA6Protein shisa-6Involved in maintenance of high-frequency synaptic transmission at hippocampal CA3-CA1 synapses.
PIRTPhosphoinositide-interacting proteinRegulatory subunit of TRPV1, a molecular sensor of noxious heat and capsaicin.
GRM3Metabotropic glutamate receptor 3G-protein coupled receptor for glutamate.

Protein-family classification

Druggable: 4 · Difficult: 1 · Unknown: 4 · Druggable fraction: 0.44

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
GPCR25.3×0.258
Protease14.1×0.469
Kinase13.1×0.469
Transcription factor10.9×0.847
Other/Unknown40.8×0.847

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TACR1GPCRyesNK1_rcpt, GPCR_Rhodpsn, Neurokn_rcpt
MAST4KinaseyesProt_kinase_dom, AGC-kinase_C, PDZ
PRICKLE2Transcription factornoZnf_LIM, PET_domain, PET_prickle
ELAPOR2Other/UnknownnoMan6P_isomerase_rcpt-bd_dom_sf, Growth_fac_rcpt_cys_sf, Elapor1/2
SENP2Proteaseyes3.4.22.B71Peptidase_C48_C, Papain-like_cys_pep_sf
EVA1AOther/UnknownnoEVA1_dom, EVA1_A/B
SHISA6Other/UnknownnoShisa, Shisa_N
PIRTOther/UnknownnoPIRT
GRM3GPCRyesGPCR_3_mtglu_rcpt, GPCR_3, GPCR_3_mGluR3

Expression context

Cohort genes with no expression data: 0.

7 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)9
unknown0

Top tissues across cohort

TissueCohort genes
cartilage tissue2
colonic epithelium2
calcaneal tendon2
cortical plate2
endocervix1
male germ line stem cell (sensu Vertebrata) in testis1
subcutaneous adipose tissue1
cervix squamous epithelium1
squamous epithelium1
cauda epididymis1
oviduct epithelium1
corpus callosum1
secondary oocyte1
adrenal tissue1
liver1
right lobe of liver1
cerebellar vermis1
lateral nuclear group of thalamus1
dorsal root ganglion1
medial globus pallidus1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TACR1183broadmarkermale germ line stem cell (sensu Vertebrata) in testis, endocervix, subcutaneous adipose tissue
MAST4294ubiquitousmarkercervix squamous epithelium, cartilage tissue, squamous epithelium
PRICKLE2233ubiquitousmarkeroviduct epithelium, cauda epididymis, colonic epithelium
ELAPOR2234ubiquitousmarkercorpus callosum, secondary oocyte, calcaneal tendon
SENP2270ubiquitousmarkercalcaneal tendon, colonic epithelium, adrenal tissue
EVA1A165ubiquitousmarkerright lobe of liver, cartilage tissue, liver
SHISA6172tissue_specificyeslateral nuclear group of thalamus, cerebellar vermis, cortical plate
PIRT105tissue_specificyesdorsal root ganglion, trigeminal ganglion, medial globus pallidus
GRM3129broadmarkerendothelial cell, middle frontal gyrus, cortical plate

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
GRM32,804
SENP21,384
TACR11,350
PRICKLE21,151
SHISA61,109
MAST4943
ELAPOR2754
EVA1A613
PIRT583

Structural data

PDB: 4 · AlphaFold-only: 5 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
GRM3Q1483220
TACR1P2510315
SENP2Q9HC628
MAST4O150211

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
ELAPOR2A8MWY076.35
EVA1AQ9H8M964.06
PIRTP0C85162.97
PRICKLE2Q7Z3G656.41
SHISA6Q6ZSJ955.97

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 9 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
SUMO is proteolytically processed1475.8×0.014SENP2
Tachykinin receptors bind tachykinins1475.8×0.014TACR1
Processing and activation of SUMO1317.2×0.014SENP2
Class C/3 (Metabotropic glutamate/pheromone receptors)173.2×0.044GRM3
SUMOylation140.8×0.063SENP2
Cargo recognition for clathrin-mediated endocytosis126.2×0.067TACR1
Post-translational protein phosphorylation125.0×0.067EVA1A
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)121.6×0.067EVA1A
Clathrin-mediated endocytosis121.3×0.067TACR1
G alpha (q) signalling events114.3×0.088TACR1
G alpha (i) signalling events19.7×0.117GRM3
Post-translational protein modification14.8×0.209SENP2
Metabolism of proteins13.1×0.286SENP2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 9 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
behavioral response to pain2197.1×0.004TACR1, PIRT
regulation of DNA endoreduplication11872.4×0.016SENP2
negative regulation of nervous system development11872.4×0.016ELAPOR2
angiotensin-mediated drinking behavior1624.1×0.017TACR1
regulation of AMPA glutamate receptor clustering1624.1×0.017SHISA6
aggressive behavior1468.1×0.017TACR1
phospholipase C-activating tachykinin receptor signaling pathway1468.1×0.017TACR1
smooth muscle contraction involved in micturition1468.1×0.017TACR1
detection of abiotic stimulus1374.5×0.017TACR1
response to ozone1374.5×0.017TACR1
positive regulation of synaptic transmission, cholinergic1374.5×0.017TACR1
sperm ejaculation1374.5×0.017TACR1
positive regulation of epidermis development1374.5×0.017ELAPOR2
protein localization to axon1374.5×0.017PRICKLE2
regulation of smooth muscle cell migration1267.5×0.017TACR1
operant conditioning1267.5×0.017TACR1
connective tissue replacement1267.5×0.017EVA1A
positive regulation of action potential1234.1×0.017TACR1
labyrinthine layer development1234.1×0.017SENP2
positive regulation of uterine smooth muscle contraction1234.1×0.017TACR1
postsynaptic neurotransmitter receptor diffusion trapping1234.1×0.017SHISA6
tachykinin receptor signaling pathway1208.1×0.017TACR1
protein desumoylation1208.1×0.017SENP2
positive regulation of lymphocyte proliferation1208.1×0.017TACR1
Wnt signaling pathway222.2×0.017SENP2, SHISA6
positive regulation of hormone secretion1187.2×0.018TACR1
cardiac left ventricle morphogenesis1170.2×0.019EVA1A
negative regulation of adenylate cyclase activity1156.0×0.019GRM3
positive regulation of vascular permeability1144.0×0.019TACR1
regulation of smooth muscle cell proliferation1144.0×0.019TACR1

Therapeutics

Drugs indicated for this disease

12 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
CiclopiroxApproved (phase 4)
Coal TarApproved (phase 4)
Cortisone AcetateApproved (phase 4)
DexamethasoneApproved (phase 4)
Fluocinolone AcetonideApproved (phase 4)
HydrocortisoneApproved (phase 4)
Hydrocortisone ButyrateApproved (phase 4)
KetoconazoleApproved (phase 4)
PrednisoloneApproved (phase 4)
PrednisoneApproved (phase 4)
Salicylic AcidApproved (phase 4)
Selenium SulfideApproved (phase 4)
Clobetasol PropionatePhase 3 (in late-stage trials)
Tacrolimus AnhydrousPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Azelaic Acid, Omiganan, PAC-14028, Pimecrolimus, Roflumilast, Ruxolitinib.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 2 · Phased (≥1): 3 · Undrugged: 6

Druggability breadth: 4 of 9 evidence-associated genes (44%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
TACR1CLOTRIMAZOLE

Top cohort targets by molecule count

SymbolMoleculesMax phase
TACR1424
GRM333
SENP212
MAST400
PRICKLE200
ELAPOR200
EVA1A00
SHISA600
PIRT00

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
CLOTRIMAZOLE4TACR1
ARIPIPRAZOLE4TACR1
AMOXAPINE4TACR1
THIOTHIXENE4TACR1
FIDAXOMICIN4TACR1
APREPITANT4TACR1
CYCLOSPORINE4TACR1
RITONAVIR4TACR1
TERFENADINE4TACR1
NETUPITANT4TACR1
NILOTINIB4TACR1
BOSUTINIB4TACR1
ASTEMIZOLE4TACR1
ROLAPITANT4TACR1
LANSOPRAZOLE4TACR1
PAROXETINE4TACR1
DEXTROMETHORPHAN4TACR1
HALOPERIDOL4TACR1
ACLIDINIUM BROMIDE4TACR1
TRAZODONE4TACR1
NEFAZODONE4TACR1
ITRACONAZOLE4TACR1
DOXAZOSIN4TACR1
CARVEDILOL4TACR1
ECONAZOLE4TACR1
TAMOXIFEN4TACR1
MICONAZOLE4TACR1
CASOPITANT3TACR1
SAREDUTANT3TACR1
SERLOPITANT3TACR1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
TACR1620Binding:506, Functional:111, ADMET:3
GRM3180Functional:102, Binding:76, ADMET:2
SENP215Binding:15
MAST413Binding:13

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
SENP23.4.22.B71

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
TACR1620
GRM3180

Pharmacogenomics

Cohort genes with a PharmGKB record: 9; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
CLOTRIMAZOLE4TACR1
ARIPIPRAZOLE4TACR1
AMOXAPINE4TACR1
THIOTHIXENE4TACR1
FIDAXOMICIN4TACR1
APREPITANT4TACR1
CYCLOSPORINE4TACR1
RITONAVIR4TACR1
TERFENADINE4TACR1
NETUPITANT4TACR1
NILOTINIB4TACR1
BOSUTINIB4TACR1
ASTEMIZOLE4TACR1
ROLAPITANT4TACR1
LANSOPRAZOLE4TACR1
PAROXETINE4TACR1
DEXTROMETHORPHAN4TACR1
HALOPERIDOL4TACR1
ACLIDINIUM BROMIDE4TACR1
TRAZODONE4TACR1
NEFAZODONE4TACR1
ITRACONAZOLE4TACR1
DOXAZOSIN4TACR1
CARVEDILOL4TACR1
ECONAZOLE4TACR1
TAMOXIFEN4TACR1
MICONAZOLE4TACR1
CASOPITANT3TACR1
SAREDUTANT3TACR1
SERLOPITANT3TACR1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1TACR1
BPhased (≥1) drug, not yet approved2SENP2, GRM3
CDruggable family + PDB, no drug1MAST4
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug5PRICKLE2, ELAPOR2, EVA1A, SHISA6, PIRT

Undrugged target profiles

6 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
MAST413—
PRICKLE20—
ELAPOR20—
EVA1A0—
SHISA60—
PIRT0—

Clinical trials & evidence

Clinical trials

Clinical trials: 37.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified17
PHASE210
PHASE44
PHASE33
PHASE12
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01139749PHASE4UNKNOWNEfficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
NCT01214434PHASE4COMPLETEDPromiseb Topical Cream for Cradle Cap
NCT01591070PHASE4COMPLETEDProactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis
NCT03567980PHASE4COMPLETEDA Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
NCT00565279PHASE3COMPLETEDEfficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis
NCT02004860PHASE3COMPLETEDTacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis
NCT04973228PHASE3COMPLETEDTrial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
NCT00403559PHASE2COMPLETEDA 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
NCT00991198PHASE2COMPLETEDThe Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
NCT01254162PHASE2COMPLETEDProof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers
NCT01703793PHASE2COMPLETEDSafety and Efficacy Study in Subjects With Seborrheic Dermatitis
NCT02749383PHASE2COMPLETEDA Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis
NCT03688971PHASE2UNKNOWNOmiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
NCT04091646PHASE2COMPLETEDSafety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
NCT04445987PHASE2COMPLETEDLong-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
NCT05787860PHASE2COMPLETEDRuxolitinib in Seborrheic Dermatitis
NCT06013371PHASE2TERMINATEDPDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
NCT07404033PHASE1NOT_YET_RECRUITINGZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis
NCT00767546PHASE1UNKNOWNBotulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
NCT03114111EARLY_PHASE1COMPLETEDPilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis
NCT05942248Not specifiedRECRUITINGThe Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
NCT07063615Not specifiedACTIVE_NOT_RECRUITINGA Clinical Study to Assess the Safety and Effectiveness of Scalp Cream for Symptom Relief and Microbiome Balance in Mild-moderate Seborrheic Dermatitis Patients.
NCT07549828Not specifiedNOT_YET_RECRUITINGSebum Metabolomics and Lipidomics for Clinical Applications
NCT00830908Not specifiedCOMPLETEDHairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis
NCT01024374Not specifiedUNKNOWNEvaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face
NCT01203189Not specifiedCOMPLETEDSeborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
NCT01315951Not specifiedTERMINATEDPetrolatum’s Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation
NCT02349854Not specifiedCOMPLETEDNeurobiology of the Scalp in Seborrheic Dermatitis
NCT02494297Not specifiedCOMPLETEDDUS on the Prescribing Indications for CPA/EE in 5 European Countries
NCT02656368Not specifiedCOMPLETEDSafety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis
NCT03807453Not specifiedCOMPLETEDComparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients
NCT04472546Not specifiedCOMPLETEDUse of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis
NCT05105139Not specifiedCOMPLETEDStudy to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
NCT05319444Not specifiedSUSPENDEDCleansing Device for the Treatment of Scalp and Hair Conditions
NCT07297446Not specifiedCOMPLETEDPhenotypic and Functional Profile of Peripheral Blood Lymphomonocytes in Seborrheic Dermatitis.
NCT07428915Not specifiedCOMPLETEDEvaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
NCT07576023Not specifiedCOMPLETEDA 4-weeks Comparative Study of Cosmetic Product Versus Standard Medical Care in Subjects With Seborrheic Dermatitis

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CICLOPIROX42
KETOCONAZOLE42
LEVOKETOCONAZOLE42
BACITRACIN41
CLIOQUINOL41
CRISABOROLE41
ISOTRETINOIN41
PIMECROLIMUS41
POLYMYXIN B41
ROFLUMILAST41
SALICYLIC ACID41
TRICLOSAN41
COAL TAR31
OMIGANAN31
POWDERED CELLULOSE31
ALLANTOIN21
IDREBORMILAST21
CHEMBL32886302
CHEMBL7502
CHEMBL123008001
CHEMBL239751301
CHEMBL37375601
CHEMBL376436301
CHEMBL398973801
CHEMBL409694501
CHEMBL420955601
CHEMBL430330601
CHEMBL463695801
CHEMBL528108001

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 71

This page pulls from 71 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd10cmintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot